References
- Werkö L. The enigma of coronary heart disease and its prevention. Acta Med Scand. 1987; 221: 323–33
- Werkö L. Risk factors and coronary heart disease – facts or fancy?. Am Heart J. 1976; 91: 87–97
- Stehbens WE. An appraisal of the epidemic rise of coronary heart disease and its decline. Lancet 1987; I: 606–10
- Sones FM, Jr, Shirey EK, Proudfit WL, Westcott RN. Cine-coronary arteriography. Circulation. 1959; 29: 773–83
- Cramér K, Paulin S, Werkö L. Coronary angiographic findings in correlation with age, body weight, blood pressure, serum lipids and smoking habits. Circulation. 1966; 33: 888–900
- Werkö L. Symposium on coronary arteriography. Introduction. Am J Cardiology. 1967; 19: 482–5
- Werkö L. Analysis of the MRFIT screenees: A methodological study. J Int Med. 1995; 217: 507–18
- Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S). Lancet. 1884; 334: 1383–9
- Multiple Risk Factor Intervention Trial Research Group. MRFIT: Risk factor changes and mortality. JAMA. 1982; 248: 1465–77
- Wilhelmsen L, Berglund G, Elmfeldt D, Tibblin G, Wedel H, Pemmert K, et al. The multifactor primary prevention trial in Göteborg, Sweden. Eur Heart J. 1986; 7: 279–88
- Wentworth D, Neaton JD, Rasmussen WL. An evaluation of the Social Security Administration MBR file and the National Death Index in the ascertainment of vital status. Am J Publ Health. 1983; 73: 1270–4
- Neaton J, Grimm RHJr, Cutler JA. Recruitment of participants for the MRFIT. Centr Clin Trials 1987; 8(Suppl): 91S–108S
- Martin MJ, Hullley SB, Browner WS, Kuller LH, Wentworth D. Serum cholesterol, blood pressure and mortality: Implications from a cohort of 361 662 men. Lancet. 1986; II: 933–6
- Stamler J, Wentworth D, Neaton J. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the MRFIT. JAMA. 1986; 256: 2823–8
- Neaton JD, Blackburn H, Jacobs D, Kuller L, Duck-Joo L, Sherwin R, et al. Serum cholesterol level and mortality findings for men screened in the MRFIT. Arch Int Med. 1992; 152: 1490–500
- Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996; 348: 1079–82
- Berenson A. New questions on treating cholesterol. New York Times. Jan 17 2008
- Goldacre B. A bad pharma story. The Guardian. Jan 5 2008
- Winslow R, Rubenstein S. Study deals setback to cholesterol drug. Wall Street Journal. Jan 15 2008
- Cover Story. Do cholesterol drugs do any good?. Business Week. Jan 17 2008
- Tanne JH. NIH needs to tackle conflicts of interest. Brit Med J. 2008; 336: 235
- Richardson E. Letter to the Swedish Board of Health and Welfare. Personal communication.
- Collins R, MacMahon S. Reliable assessment of the effects of treatment on mortality and major morbidity. I: Clinical trials. Lancet. 2001; 357: 373–80
- Collins R, MacMahon S. Reliable assessment of the effects of treatment on mortality and major morbidity. II: Observational studies. Lancet. 2001; 357: 455–62
- Gwynne JT. The trouble with cholesterol and decision making. JAMA. 1991; 266: 1696–8
- Irwig L, Glasziou P, Wilson A, Macaskill P. Estimating an individual's true cholesterol level and response to intervention. JAMA. 1991; 266: 1678–85
- Ulbricht TLV, Southgate DAT. Coronary heart disease: Seven dietary factors. Lancet. 1991; 338: 985–992